How to Watch ‘Kara Swisher Wants to Live Forever,’ New Investigative Series on the Longevity Industry

Why It Matters

The series spotlights a multi‑billion‑dollar sector where hype often outpaces science, influencing consumer spending and investor interest. Its wide, free‑trial distribution amplifies public scrutiny of anti‑aging claims and could shape regulatory attention.

Key Takeaways

• Series premieres April 11, runs six weeks on CNN
• Swisher interviews longevity leaders like Johnson, Altman, Galloway
• Free trials let cord‑cutters watch without paying
• Streaming options cost $19.99‑$89.99 per month after trial

Pulse Analysis

The longevity market has exploded into a $300 billion industry, driven by venture capital, celebrity endorsement, and a cultural obsession with extending healthspan. Yet the sector is riddled with unproven claims, regulatory gray zones, and stark disparities in who can access cutting‑edge therapies. By dedicating a six‑part series to this space, Kara Swisher provides a rare, journalistic deep‑dive that separates scientific breakthroughs from marketing hype, offering investors and consumers a clearer picture of where real value lies.

Swisher’s reputation for cutting‑through tech buzz makes her an ideal host for this investigation. Her lineup—featuring biotech visionary Bryan Johnson, OpenAI co‑founder Sam Altman, and marketing professor Scott Galloway—ensures conversations that blend scientific insight with business strategy. The format, which blends personal experimentation (ketamine, red‑light therapy) with high‑profile interviews, adds credibility and entertainment value, positioning the series as both a consumer guide and a barometer for industry trends.

The distribution strategy leverages the current streaming ecosystem: by airing on CNN and simultaneously offering free‑trial access through DirecTV, Sling, and Hulu + Live TV, the series reaches both traditional cable viewers and cord‑cutters. This approach maximizes audience size while lowering entry barriers, potentially driving higher ad revenues and attracting sponsors eager to tap the longevity market. For the industry, heightened visibility could accelerate demand for validated treatments and pressure regulators to tighten oversight, ultimately shaping the next wave of anti‑aging innovation.